Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 66

Sort by

Sort Order Select

Journal Articles

A Phase 1/2 Study of Carfilzomib, Iberdomide and Dexamethasone (KID) in Patients with Newly Diagnosed Transplant-Eligible Multiple Myeloma

Blood (2023) 142 (Supplement 1): 2022.

https://doi.org/10.1182/blood-2023-189907

Published: 2023

Journal Articles

A Real-World Comparison of Idecabtagene Vicleucel and Ciltacabtagene Autoleucel CAR-T Therapy: A Single Center Experience for Relapsed/ Refractory Multiple Myeloma

Sarvarinder Kaur Gill, Noa Biran, Pooja Phull, David H. Vesole, David S. Siegel, Harsh Parmar

Blood (2023) 142 (Supplement 1): 4717.

https://doi.org/10.1182/blood-2023-190583

Published: 2023

Journal Articles

Single-Center Experience of Carfilzomib-Based Combinations for Patients with Lymphoplasmacytic Lymphoma

Harsh Parmar, Noa Biran, Pooja Phull, David H. Vesole, David S. Siegel

Blood (2023) 142 (Supplement 1): 1684.

https://doi.org/10.1182/blood-2023-190155

Published: 2023

Journal Articles

Teclistamab Demonstrates Clinical Activity in Real-World Patients Ineligible for the Pivotal Majestec-1 Trial

Beth Gordon, Lindsay Fogel, Gaurav Varma, Mateo Mejia Saldarriaga, Jaeil Ahn, Adolfo Aleman, Jessica Caro, Xiaoyi Chen, Jorge Monge, Harsh Parmar, David Kaminetzky, Tibor Moskovits, David S. Siegel, Gareth J. Morgan, Ruben Niesvizky, Noa Biran, Faith E. Davies

Blood (2023) 142 (Supplement 1): 4741.

https://doi.org/10.1182/blood-2023-181304

Published: 2023

Journal Articles

A Phase 2b Study of Selinexor in Combination with Carfilzomib, Daratumumab, or Pomalidomide in Patients with Multiple Myeloma Relapsing on Current Therapy

Blood (2023) 142 (Supplement 1): 6714.

https://doi.org/10.1182/blood-2023-187011

Published: 2023

Journal Articles

Sequential Administration of Selinexor and CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma

Sarvarinder Kaur Gill, Noa Biran, Pooja Phull, David H. Vesole, David S. Siegel, Harsh Parmar

Blood (2023) 142 (Supplement 1): 6930.

https://doi.org/10.1182/blood-2023-190413

Published: 2023

Journal Articles

Prommis Trial Prospectively Demonstrates the Efficacy of SKY92 Risk Stratification in Newly Diagnosed Multiple Myeloma Patients

Noa Biran, Binod Dhakal, Ruben Niesvizky, Suzanne Lentzsch, John T. McKay, David H. Vesole, Ajay K. Nooka, Barry Paul, Parameswaran N. Hari, Lisette Stork-Sloots, Silvia D'Ambrosi, Rowan Kuiper, Martin van Vliet, David S. Siegel, Saad Z Usmani, Frits van Rhee

Blood (2023) 142 (Supplement 1): 3386.

https://doi.org/10.1182/blood-2023-180761

Published: 2023

Journal Articles

Gut Microbiota Diversity and Composition Is Associated with High-Risk Myeloma

Rena Feinman, Ariel Aptekmann, Iriana Colorado, Samuel Roy, Katelyn Quino, Noreen Ahmed, Adolfo Aleman, Rashmi Unawane, Joshua Zenreich, Alana Barofsky, Kashish Bhatt, Michele L. Donato, Noa Biran, David S. Siegel

Blood (2023) 142 (Supplement 1): 3294.

https://doi.org/10.1182/blood-2023-190108

Published: 2023

Journal Articles

Unveiling the Discrepancy in Multiple Myeloma Risk Classification between Clinical Practice and SKY92 Test and the Impact on Survival

Blood (2023) 142 (Supplement 1): 2013.

https://doi.org/10.1182/blood-2023-181905

Published: 2023

Journal Articles

Talquetamab + Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Safety and Preliminary Efficacy Results from the Phase 1b MonumenTAL-2 Study

Jeffrey Matous, Noa Biran, Aurore Perrot, Jésus G Berdeja, Kathleen Dorritie, Janine Van Elssen, Emma Searle, Cyrille Touzeau, Sébastien Anguille, Deeksha Vishwamitra, Ashley Nguyen, Debopriya Ghosh, Elizabeth Shearin, Katherine Thornton, Damiette Smit, Hang Quach

Blood (2023) 142 (Supplement 1): 1014.

https://doi.org/10.1182/blood-2023-187706

Published: 2023

Journal Articles

Comparison of Fludarabine/Cyclophosphamide Vs Bendamustine As Lymphodepleting Regimen for CAR-T: A Safety and Efficacy Analysis in Patients with Relapsed/ Refractory Multiple Myeloma

Sarvarinder Kaur Gill, Noa Biran, Pooja Phull, Sukhdeep Kaur, Hyung C Suh, Christina Cho, Michele L. Donato, Scott D Rowley, David H. Vesole, David S. Siegel, Harsh Parmar

Blood (2023) 142 (Supplement 1): 6903.

https://doi.org/10.1182/blood-2023-190507

Published: 2023

Journal Articles

Using Next Generation Sequencing of Flow Cytometry CD Markers and Machine Learning As a Replacement to Flow Cytometry Analysis for the Diagnosis of Hematologic Neoplasms

Maher Albitar, Hong Zhang, Andrew Ip, Wanlong Ma, James McCloskey, Katherine Linder, Jeffrey Justin Estella, Jamie Koprivnikar, Noa Biran, David S. Siegel, Ahmad Charifa, Arash Mohtashamian, Andrew L Pecora, Andre Goy

Blood (2023) 142 (Supplement 1): 3654.

https://doi.org/10.1182/blood-2023-187041

Published: 2023

Journal Articles

The Mydrug Platform Trial: Efficacy and Safety of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone in Patients with Functionally High-Risk Multiple Myeloma

Shaji K Kumar, Craig C Hofmeister, Noa Biran, Gurbakhash Kaur, Jing Christine Ye, Jeffrey A. Zonder, Umar Syed, Jennifer Yesil, Karen Woolley, George Mulligan, Hearn J. Cho

Blood (2022) 140 (Supplement 1): 4434–4435.

https://doi.org/10.1182/blood-2022-163737

Published: 2022

Journal Articles

Effect of Daratumumab on Stem Cell Mobilization and Engraftment Kinetics Post Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma

Samir Oza, Ronit Slotky, Pranay Vissa, Pooja Phull, Sukhdeep Kaur, Hyung C. Suh, Michele L. Donato, Scott D. Rowley, Noa Biran, David H. Vesole, David Siegel, Harsh Parmar

Blood (2022) 140 (Supplement 1): 10441–10442.

https://doi.org/10.1182/blood-2022-171098

Published: 2022

Journal Articles

Outcomes of Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma Receiving Salvage Cytotoxic Therapy with Supportive Stem Cell Boost

Ayrton Bangolo, Samir Oza, Ronit Slotky, Aimee Chappell, David Siegel, Harsh Parmar, Noa Biran, David H. Vesole, Pooja Phull

Blood (2022) 140 (Supplement 1): 10041–10042.

https://doi.org/10.1182/blood-2022-171012

Published: 2022

Journal Articles

Gut Microbiome Composition Is Associated with Engraftment Syndrome in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Blood (2022) 140 (Supplement 1): 4843–4844.

https://doi.org/10.1182/blood-2022-168934

Published: 2022

Journal Articles

The Clinical Characteristics and Epidemiology of Extramedullary Multiple Myeloma over the Past Two Decades

Blood (2022) 140 (Supplement 1): 12521–12522.

https://doi.org/10.1182/blood-2022-170783

Published: 2022

Journal Articles

Selinexor-Based Regimens in Patients with Multiple Myeloma after Prior Anti-B-Cell Maturation Antigen Treatment

Blood (2021) 138 (Supplement 1): 2751.

https://doi.org/10.1182/blood-2021-150998

Published: 2021

Journal Articles

Once Weekly Oral Selinexor, Pomalidomide, and Dexamethasone in Relapsed Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 2748.

https://doi.org/10.1182/blood-2021-148759

Published: 2021

Journal Articles

Inferior Outcomes of Patients with Quad and Penta-Refractory Multiple Myeloma (MM) Compared to Those of Patients Who Have Been Quad and Penta Exposed

Sarvarinder K Gill, Rashmi Unawane, Shuqi Wang, Adolfo Aleman, Michelle Serna, Fideliza Perez-Manon, Gina Rivieccio, David S. Siegel, David H. Vesole, Harsh Parmar, Jaeil Ahn, Noa Biran

Blood (2021) 138 (Supplement 1): 4742.

https://doi.org/10.1182/blood-2021-153556

Published: 2021

NARROW

A Phase 1/2 Study of Carfilzomib, Iberdomide and Dexamethasone (KID) in Patients with Newly Diagnosed Transplant-Eligible Multiple Myeloma

A Real-World Comparison of Idecabtagene Vicleucel and Ciltacabtagene Autoleucel CAR-T Therapy: A Single Center Experience for Relapsed/ Refractory Multiple Myeloma

Single-Center Experience of Carfilzomib-Based Combinations for Patients with Lymphoplasmacytic Lymphoma

Teclistamab Demonstrates Clinical Activity in Real-World Patients Ineligible for the Pivotal Majestec-1 Trial

A Phase 2b Study of Selinexor in Combination with Carfilzomib, Daratumumab, or Pomalidomide in Patients with Multiple Myeloma Relapsing on Current Therapy

Sequential Administration of Selinexor and CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma

Prommis Trial Prospectively Demonstrates the Efficacy of SKY92 Risk Stratification in Newly Diagnosed Multiple Myeloma Patients

Gut Microbiota Diversity and Composition Is Associated with High-Risk Myeloma

Unveiling the Discrepancy in Multiple Myeloma Risk Classification between Clinical Practice and SKY92 Test and the Impact on Survival

Talquetamab + Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Safety and Preliminary Efficacy Results from the Phase 1b MonumenTAL-2 Study

Comparison of Fludarabine/Cyclophosphamide Vs Bendamustine As Lymphodepleting Regimen for CAR-T: A Safety and Efficacy Analysis in Patients with Relapsed/ Refractory Multiple Myeloma

Using Next Generation Sequencing of Flow Cytometry CD Markers and Machine Learning As a Replacement to Flow Cytometry Analysis for the Diagnosis of Hematologic Neoplasms

The Mydrug Platform Trial: Efficacy and Safety of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone in Patients with Functionally High-Risk Multiple Myeloma

Effect of Daratumumab on Stem Cell Mobilization and Engraftment Kinetics Post Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma

Outcomes of Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma Receiving Salvage Cytotoxic Therapy with Supportive Stem Cell Boost

Gut Microbiome Composition Is Associated with Engraftment Syndrome in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

The Clinical Characteristics and Epidemiology of Extramedullary Multiple Myeloma over the Past Two Decades

Selinexor-Based Regimens in Patients with Multiple Myeloma after Prior Anti-B-Cell Maturation Antigen Treatment

Once Weekly Oral Selinexor, Pomalidomide, and Dexamethasone in Relapsed Refractory Multiple Myeloma

Inferior Outcomes of Patients with Quad and Penta-Refractory Multiple Myeloma (MM) Compared to Those of Patients Who Have Been Quad and Penta Exposed

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only